Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

8.770 +0.530 (+6.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharm Ord

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
What 5 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Over the past 3 months, 5 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ: 
Via Benzinga
Aurinia Pharmaceuticals Inc (AUPH) Q3 2021 Earnings Call Transcript
AUPH earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on. 
Via The Motley Fool
Aurinia Pharmaceuticals: Q3 Earnings Insights
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Analyzing Aurinia Pharmaceuticals's Unusual Options Activity
Aurinia Pharmaceuticals (NASDAQ:AUPH) shares experienced ... 
Via Benzinga
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
No Negative Reaction
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
Upgrades For Boot Barn Holdings Inc (NYSE: 
Via Benzinga
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Cyber Currency
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck. 
Via Talk Markets
Aurinia Rockets — Again — On Rumored Bristol Marriage; Could Others Make A Pass?
Aurinia stock hit another record Monday on Bristol's rumored takeover. 
Via Investor's Business Daily
55 Biggest Movers From Friday
Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World... 
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Blasting Higher Today
The biotech is reportedly in buyout talks with Bristol Myers Squibb. 
Via The Motley Fool
Aurinia Pharma Stock Pops On Reports Of Looming Bristol Myers Takeover
Bristol is reportedly interested in acquiring Aurinia, according to reports that sent AUPH stock flying before it was halted. 
Via Investor's Business Daily
More Chinese Trouble
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
Pharma, Tech and Finance
Good news on some drugs was not enough to boost stock markets. 
Via Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
Sunday Special
I have a taste for nuclear electricity which France pioneered decades ago, building power stations along the Loire Valley and in other regions. So I took my taste for uranium into my US holdings. 
Via Talk Markets
Topics Energy
Exposures Electricity Generation
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Post-Rosh Hashanah, Sell?
As the saying goes, sell Rosh Hashanah and buy Yom Kippur. Does it apply this year? 
Via Talk Markets
Aurinia Pharmaceuticals finalizes acquisition agreement with Leading Pharma Giant
Via Get News
Aurinia Answers 'What's Next?' And Investors Punish AUPH Stock
Aurinia snagged a pair of early-stage drugs for roughly $6.8 million on Tuesday, but AUPH stock tumbled into a key moving average. 
Via Investor's Business Daily
Aurinia Adds Two Assets To Expand Its Immunology Pipeline
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was... 
Via Benzinga
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.